发明名称 |
EPIGENETIC SILENCING OF NMT2 |
摘要 |
The finding that multiple cancers lack one of two NMTs, while stromal and normal tissues do not, enables the treatment of NMT2-deficient cancer cells with an NMT inhibitor. It is shown herein that NMT2 expression is reduced or eliminated in certain cancers, and in one example lymphomas, via an epigenetic mechanism(s). Reduction or elimination of NMT2 expression renders the cancer sensitive inhibitors of NMT. |
申请公布号 |
WO2017011907(A1) |
申请公布日期 |
2017.01.26 |
申请号 |
WO2016CA50846 |
申请日期 |
2016.07.18 |
申请人 |
PACYLEX PHARMACEUTICALS INC. |
发明人 |
BERTHIAUME, Luc G.;BEAUCHAMP, Erwan |
分类号 |
C12Q1/68;A61B5/00;A61B5/06;A61K31/4439;A61K31/7088;A61K38/00;A61K39/395;A61P35/00;C07H21/04;G01N33/48;G01N33/50 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|